肝细胞癌治疗的突破性进展
本综述详述肝细胞癌各分期治疗的重大突破:肿瘤生物学理解加深使更多患者适合根治性手术,降期至米兰标准者可获可接受的移植结局,高危患者辅助治疗显著改善无复发生存;系统治疗领域新药及免疫检查点抑制剂联合方案使约30%患者出现客观缓解,中位生存接近2年,多学科诊疗与临床结局改善相关。
要点
- 经过筛选、肿瘤降期至米兰标准的患者可获得可接受的移植后结局。
- 高复发风险患者切除或消融后辅助治疗显著改善无复发生存。
- 系统治疗中约30%患者出现客观缓解,中位生存接近2年。
核心结论
- 肝细胞癌各分期治疗的多项突破为改善其不良预后带来希望,多学科诊疗至关重要且与临床结局改善相关。
研究设计与样本
- 综述,总结肝细胞癌各分期治疗的重大突破及其临床应用,并指出需进一步研究的领域。
主要发现
- 手术与局部消融技术无重大变化,但肿瘤生物学理解加深使更多患者适合接受根治性手术。
- 经筛选、肿瘤降期进入米兰标准的患者可获得可接受的移植后结局。
- 高复发风险患者切除或消融后辅助治疗显著改善无复发生存。
- 肝局限性疾病不适合根治性手术者,历史上经动脉化疗栓塞(TACE)为治疗选择,现更多认识到「不适合TACE」患者可能更适合系统治疗。
- 系统治疗领域出现多个一线和二线新药(包括免疫检查点抑制剂联合方案),约30%患者出现客观缓解,中位生存接近2年。
关键数值与推荐
- 系统治疗中约30%患者出现客观缓解,中位生存接近2年。
- 免疫检查点抑制剂的应用重新激发对早期肿瘤阶段联合治疗的关注,多项III期试验正在进行中。
临床怎么用
- 多学科诊疗至关重要,且与临床结局改善相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages provide hope to improve its dismal prognosis. Although surgical and local ablative therapies have few significant changes in technique, an improved understanding of tumor biology has facilitated increase numbers of patients who are now eligible to undergo curative-intent procedures. Most notably, acceptable post-transplant outcomes can be achieved in well selected patients whose tumors are downstaged into Milan Criteria. Adjuvant therapy in patients at high risk of recurrence also significantly improves recurrence-free survival after resection or ablation. For patients with liver-localized disease who are not eligible for curative-intent procedures, transarterial chemoembolization (TACE) was historically the treatment modality of choice, regardless of tumor burden; however, there is now increased recognition of patients who are "TACE unsuitable" and may be better treated with systemic therapy. The greatest evolution in HCC treatment options has occurred with systemic therapy, where several new agents are now available in the first- and second-line setting, including immune checkpoint inhibitor combinations. Objective responses are observed in approximately 30% of patients and median survival is approaching 2 years. The availability of immune checkpoint inhibitors has renewed interest in combination therapies for earlier tumor stages, with several phase III trials ongoing. Considering increasing complexities of HCC care, requiring decisions between therapies delivered by different providers, multidisciplinary care is critical and is associated with improved clinical outcomes. In this review, we detail major breakthroughs in HCC therapy, how these breakthroughs can be applied in clinical practice, and remaining areas in need of further research.
引用
- Singal AG, Kudo M, Bruix J, et al. Breakthroughs in Hepatocellular Carcinoma Therapies. Clin Gastroenterol Hepatol. 2023. PMID: 36813012. doi:10.1016/j.cgh.2023.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。